-
Nintedanib: a new treatment for idiopathic pulmonary fibrosis
Vincent Cottin
Drug Evaluation: Clinical Investigation
-
Nintedanib: a new treatment for idiopathic pulmonary fibrosis
Vincent Cottin
Drug Evaluation: Clinical Investigation
-
Nintedanib: a new treatment for idiopathic pulmonary fibrosis
Vincent Cottin
Drug Evaluation: Clinical Investigation
-
Nintedanib: a new treatment for idiopathic pulmonary fibrosis
Vincent Cottin
Drug Evaluation: Clinical Investigation
-
Nintedanib: a new treatment for idiopathic pulmonary fibrosis
Vincent Cottin
Drug Evaluation: Clinical Investigation
-
Nintedanib: a new treatment for idiopathic pulmonary fibrosis
Vincent Cottin
Drug Evaluation: Clinical Investigation
-
Nintedanib: a new treatment for idiopathic pulmonary fibrosis
Vincent Cottin
Drug Evaluation: Clinical Investigation
-
Nintedanib: a new treatment for idiopathic pulmonary fibrosis
Vincent Cottin
Drug Evaluation: Clinical Investigation
-
Monitoring rules for toxicity in Phase II oncology trials
Anastasia Ivanova, Guochen Song, Olga Marchenko & Stergios Moschos
Clinical Trail Perspective: Clinical Investigation
-
Monitoring rules for toxicity in Phase II oncology trials
Anastasia Ivanova, Guochen Song, Olga Marchenko & Stergios Moschos
Clinical Trail Perspective: Clinical Investigation
-
Monitoring rules for toxicity in Phase II oncology trials
Anastasia Ivanova, Guochen Song, Olga Marchenko & Stergios Moschos
Clinical Trail Perspective: Clinical Investigation
-
Monitoring rules for toxicity in Phase II oncology trials
Anastasia Ivanova, Guochen Song, Olga Marchenko & Stergios Moschos
Clinical Trail Perspective: Clinical Investigation
-
Monitoring rules for toxicity in Phase II oncology trials
Anastasia Ivanova, Guochen Song, Olga Marchenko & Stergios Moschos
Clinical Trail Perspective: Clinical Investigation
-
Monitoring rules for toxicity in Phase II oncology trials
Anastasia Ivanova, Guochen Song, Olga Marchenko & Stergios Moschos
Clinical Trail Perspective: Clinical Investigation
-
Monitoring rules for toxicity in Phase II oncology trials
Anastasia Ivanova, Guochen Song, Olga Marchenko & Stergios Moschos
Clinical Trail Perspective: Clinical Investigation
-
Monitoring rules for toxicity in Phase II oncology trials
Anastasia Ivanova, Guochen Song, Olga Marchenko & Stergios Moschos
Clinical Trail Perspective: Clinical Investigation
-
Study results suggest increasing disclosure in industry-sponsored clinical studies
News and Views: Clinical Investigation
-
Study results suggest increasing disclosure in industry-sponsored clinical studies
News and Views: Clinical Investigation
-
Study results suggest increasing disclosure in industry-sponsored clinical studies
News and Views: Clinical Investigation
-
Study results suggest increasing disclosure in industry-sponsored clinical studies
News and Views: Clinical Investigation
-
Study results suggest increasing disclosure in industry-sponsored clinical studies
News and Views: Clinical Investigation
-
Study results suggest increasing disclosure in industry-sponsored clinical studies
News and Views: Clinical Investigation
-
Study results suggest increasing disclosure in industry-sponsored clinical studies
News and Views: Clinical Investigation
-
Study results suggest increasing disclosure in industry-sponsored clinical studies
News and Views: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Primary sclerosing cholangitis clinical trials: mission impossible.... for now
Bret Lashner
Editorial: Clinical Investigation
-
Primary sclerosing cholangitis clinical trials: mission impossible.... for now
Bret Lashner
Editorial: Clinical Investigation
-
Primary sclerosing cholangitis clinical trials: mission impossible.... for now
Bret Lashner
Editorial: Clinical Investigation
-
Primary sclerosing cholangitis clinical trials: mission impossible.... for now
Bret Lashner
Editorial: Clinical Investigation
-
Primary sclerosing cholangitis clinical trials: mission impossible.... for now
Bret Lashner
Editorial: Clinical Investigation
-
Primary sclerosing cholangitis clinical trials: mission impossible.... for now
Bret Lashner
Editorial: Clinical Investigation
-
Primary sclerosing cholangitis clinical trials: mission impossible.... for now
Bret Lashner
Editorial: Clinical Investigation
-
Primary sclerosing cholangitis clinical trials: mission impossible.... for now
Bret Lashner
Editorial: Clinical Investigation
-
Neuroblastoma drug development: from lab bench to bedside?
Louis Chesler
Interview: Clinical Investigation
-
Neuroblastoma drug development: from lab bench to bedside?
Louis Chesler
Interview: Clinical Investigation
-
Neuroblastoma drug development: from lab bench to bedside?
Louis Chesler
Interview: Clinical Investigation
-
Neuroblastoma drug development: from lab bench to bedside?
Louis Chesler
Interview: Clinical Investigation
-
Neuroblastoma drug development: from lab bench to bedside?
Louis Chesler
Interview: Clinical Investigation
-
Neuroblastoma drug development: from lab bench to bedside?
Louis Chesler
Interview: Clinical Investigation
-
Neuroblastoma drug development: from lab bench to bedside?
Louis Chesler
Interview: Clinical Investigation
-
Neuroblastoma drug development: from lab bench to bedside?
Louis Chesler
Interview: Clinical Investigation
-
Essential thrombocythemia: new advances in an old disease
Clodagh Keohane , Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Essential thrombocythemia: new advances in an old disease
Clodagh Keohane , Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Essential thrombocythemia: new advances in an old disease
Clodagh Keohane , Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Essential thrombocythemia: new advances in an old disease
Clodagh Keohane , Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Essential thrombocythemia: new advances in an old disease
Clodagh Keohane , Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Essential thrombocythemia: new advances in an old disease
Clodagh Keohane , Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Essential thrombocythemia: new advances in an old disease
Clodagh Keohane , Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Essential thrombocythemia: new advances in an old disease
Clodagh Keohane , Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Assessing clinical efficacy of drugs in cancer patients: are we on the right track?
Ciro Gallo, Francesco Perrone
Editorial: Clinical Investigation
-
Assessing clinical efficacy of drugs in cancer patients: are we on the right track?
Ciro Gallo, Francesco Perrone
Editorial: Clinical Investigation
-
Assessing clinical efficacy of drugs in cancer patients: are we on the right track?
Ciro Gallo, Francesco Perrone
Editorial: Clinical Investigation
-
Assessing clinical efficacy of drugs in cancer patients: are we on the right track?
Ciro Gallo, Francesco Perrone
Editorial: Clinical Investigation
-
Assessing clinical efficacy of drugs in cancer patients: are we on the right track?
Ciro Gallo, Francesco Perrone
Editorial: Clinical Investigation
-
Assessing clinical efficacy of drugs in cancer patients: are we on the right track?
Ciro Gallo, Francesco Perrone
Editorial: Clinical Investigation
-
Assessing clinical efficacy of drugs in cancer patients: are we on the right track?
Ciro Gallo, Francesco Perrone
Editorial: Clinical Investigation
-
Assessing clinical efficacy of drugs in cancer patients: are we on the right track?
Ciro Gallo, Francesco Perrone
Editorial: Clinical Investigation
-
Developing an international network for clinical research in ophthalmology: the European Vision Institute Clinical Research Network (EVICR.net)
Jose Cunha-Vaz,Ceclia Martinho
Review Article: Clinical Investigation
-
Developing an international network for clinical research in ophthalmology: the European Vision Institute Clinical Research Network (EVICR.net)
Jose Cunha-Vaz,Ceclia Martinho
Review Article: Clinical Investigation
-
Developing an international network for clinical research in ophthalmology: the European Vision Institute Clinical Research Network (EVICR.net)
Jose Cunha-Vaz,Ceclia Martinho
Review Article: Clinical Investigation
-
Developing an international network for clinical research in ophthalmology: the European Vision Institute Clinical Research Network (EVICR.net)
Jose Cunha-Vaz,Ceclia Martinho
Review Article: Clinical Investigation
-
Developing an international network for clinical research in ophthalmology: the European Vision Institute Clinical Research Network (EVICR.net)
Jose Cunha-Vaz,Ceclia Martinho
Review Article: Clinical Investigation
-
Developing an international network for clinical research in ophthalmology: the European Vision Institute Clinical Research Network (EVICR.net)
Jose Cunha-Vaz,Ceclia Martinho
Review Article: Clinical Investigation
-
Developing an international network for clinical research in ophthalmology: the European Vision Institute Clinical Research Network (EVICR.net)
Jose Cunha-Vaz,Ceclia Martinho
Review Article: Clinical Investigation
-
Developing an international network for clinical research in ophthalmology: the European Vision Institute Clinical Research Network (EVICR.net)
Jose Cunha-Vaz,Ceclia Martinho
Review Article: Clinical Investigation